Image 1 of 1
Image 1 of 1
Image 1 of 1
Image 1 of 1
Understand if your patients are one of the 32% of patients in the UK* unable to metabolise Clopidogrel effectively with our Rapid CYP2C19 DNA Test.
With a simple cheek swab sample, you can quickly identify Clopidogrel non-responders and make evidence-based prescribing decisions without delay.
Why choose the Rapid CYP2C19 DNA Test?
Quickly find patients who cannot metabolise Clopidogrel effectively.
Reduce the risk of recurrent strokes, heart attacks and clot-related events.
Backed by NICE guidelines and helps patients excluded from current NHS and NICE criteria.
UKCA marked and registered with the MHRA for your peace of mind.
Simple, one-time test – results that patients can use for life.
Easy-to-understand report with clear recommendations.
Receive clear results within days for timely prescribing decisions.
Still deciding?
We’re here to help. Contact us or read our FAQs to learn more before you order.
——
Give your patients access to rapid CYP2C19 testing and prescribe Clopidogrel with confidence.
* This is as high as 57% in British South Asian populations
Understand if your patients are one of the 32% of patients in the UK* unable to metabolise Clopidogrel effectively with our Rapid CYP2C19 DNA Test.
With a simple cheek swab sample, you can quickly identify Clopidogrel non-responders and make evidence-based prescribing decisions without delay.
Why choose the Rapid CYP2C19 DNA Test?
Quickly find patients who cannot metabolise Clopidogrel effectively.
Reduce the risk of recurrent strokes, heart attacks and clot-related events.
Backed by NICE guidelines and helps patients excluded from current NHS and NICE criteria.
UKCA marked and registered with the MHRA for your peace of mind.
Simple, one-time test – results that patients can use for life.
Easy-to-understand report with clear recommendations.
Receive clear results within days for timely prescribing decisions.
Still deciding?
We’re here to help. Contact us or read our FAQs to learn more before you order.
——
Give your patients access to rapid CYP2C19 testing and prescribe Clopidogrel with confidence.
* This is as high as 57% in British South Asian populations